Ceria Therapeutics

Preclinical biotech company focused on developing novel therapies to treat overactive and nonproductive inflammation to promote healing.

[Ceria Therapeutics @CeriaTx]

Happy 4th of July from Ceria Therapeutics! We hope you have a restful and memorable Independence Day weekend 🎆

[Ceria Therapeutics @CeriaTx]

Learn about how our regenerative RNA therapeutic technology works to target the root causes of inflammation in these two conditions: https://t.co/MAWeKXmzIQ (2/2)

[Ceria Therapeutics @CeriaTx]

Diabetic foot ulcers (DFUs) and pressure ulcers are both chronic, hard-to-heal #wounds that are driven by persistent inflammation and impaired tissue repair. #WoundHealingAwarenessMonth (1/2)

[Ceria Therapeutics @CeriaTx]

See how we are working to address DFU's in our recent publication: https://t.co/4JHcP5Ntfh (3/3)

[Ceria Therapeutics @CeriaTx]

Let's talk about diabetic foot ulcers (DFUs) in recognition of #WoundHealingAwarenessMonth.

DFUs arise from poor circulation and nerve damage in diabetic patients and frequently progress to severe tissue loss. (1/3)

[Ceria Therapeutics @CeriaTx]

They are the leading cause of non-traumatic amputation and account for most #diabetes-related hospitalizations, with a lifetime risk of ~25% and markedly reduced life expectancy.

There are approximately 1.6 million new cases of diabetic foot ulcers per year in the U.S. (2/3)

[Ceria Therapeutics @CeriaTx]

miR146a is a naturally occurring microRNA that acts as a brake on the body’s acute inflammatory response.

Learn more in our publication exploring miR146a as a potential therapeutic target for pressure ulcers: https://t.co/9Ljdti7k8r (2/2)

[Ceria Therapeutics @CeriaTx]

#WoundHealingAwarenessMonth: Pressure ulcers (bedsores) are caused by points of sustained pressure and friction in immobilized or bedridden patients.

Annually, ~ 2.5 million individuals are affected, incurring healthcare costs of ~$11 billion. (1/2)

[Ceria Therapeutics @CeriaTx]

Read about Ceria’s commitment to build our future in partnership with the island, its people, its institutions, and its biopharmaceutical ecosystem: https://t.co/p3WXh7c6Xv

(2/2)

[Ceria Therapeutics @CeriaTx]

Thank you to to @InvestPR, @IAmBiotech, and all who joined our CEO David M. Jackson, PhD and other industry leaders on a great conversation about expanding and operating in Puerto Rico's world-class bioscience ecosystem.

We are very proud to call Puerto Rico home!

(1/2)

[Ceria Therapeutics @CeriaTx]

This #WoundHealingAwarenessMonth, we reaffirm our commitment to restoring natural healing in diabetic foot ulcers and pressure ulcers as we continue our work developing innovative solutions that target the root causes of inflammation.

Our mission: https://t.co/6FiR6FuaZG (2/2)

[Ceria Therapeutics @CeriaTx]

Chronic #wounds affect around 6.5 million people and cost billions in healthcare expenses annually in the United States alone.

A wound is considered chronic if it doesn't heal within 4 to 12 weeks despite treatment. (1/2)

[Ceria Therapeutics @CeriaTx]

Learn how Ceria Therapeutics aims to transform patient care in several critical conditions with our novel platform for RNA delivery: https://t.co/MAWeKXmzIQ (2/2)

[Ceria Therapeutics @CeriaTx]

As National Critical Care Awareness and Recognition Month nears and end, we're raising awareness for two of the most commonly seen conditions in the ICU: #sepsis and acute #kidney injury (AKI). (1/2)

[Ceria Therapeutics @CeriaTx]

Acute respiratory distress syndrome (#ARDS) accounts for 10% of intensive care unit (#ICU) admissions with a median ICU length of stay of 25 days.

Learn more about ARDS in our study on acute and ventilator-induced lung injury: https://t.co/Ac6YIHCoHe

[Ceria Therapeutics @CeriaTx]

Ceria is working to take on these urgent challenges by targeting the root causes of inflammation in acute respiratory failure.

See how we’re advancing solutions for several critical care conditions: https://t.co/MAWeKXmzIQ (2/2)

[Ceria Therapeutics @CeriaTx]

For National Critical Care Awareness and Recognition Month, we're putting a spotlight on acute lung injury (ALI), which could progress to acute respiratory distress syndrome (ARDS). #CritCare (1/2)

[Ceria Therapeutics @CeriaTx]

Learn more in our latest press release: https://t.co/p3WXh7c6Xv (2/)

[Ceria Therapeutics @CeriaTx]

We are excited to announce the execution of our decree under Puerto Rico's Act-60 (the Puerto Rico Incentives Code), completing the initial phase of the company's long-term strategic plan and establishing Puerto Rico as the home for Ceria's operations and growth. (1/2)

[Ceria Therapeutics @CeriaTx]

Ceria Therapeutics stands in support of the critical care community and remains dedicated to driving innovation in therapies that address urgent, unmet needs in life-threatening inflammatory conditions. (2/2)

[Ceria Therapeutics @CeriaTx]

May is #CritCareMonth! We celebrate and give our deepest thanks to healthcare providers in ICUs everywhere for their extraordinary perseverance and heroism when providing life-saving patient care. (1/2)